Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market to Reach $825 Million by 2017 at a CAGR of 10.5%
The "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017" analyzes and studies the major market drivers, restraints, and opportunities in Japan, China, India, South Korea, Indonesia, Malaysia, Australia, New Zealand, and Rest of Asia.
View full press release